Related Experiment Video
Updated: Jan 19, 2026
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
Published on: April 22, 2019
Progress in targeted therapeutic drugs for oral squamous cell carcinoma
Lian Liu1, Jili Chen1, Xinjia Cai1
1Department of Oral Pathology, Xiangya Stomatological Hospital, Central South University, 410078, Changsha, Hunan, China.
Abstract:
With the rapid development of biomedicine, people have a deeper understanding with the biological characteristics of malignant tumors, and begin to notice that in most tumors, there are over-expression of several molecules such as epidermal growth factor receptor(EGFR), vascular endothelial growth factor (VEGF) and its receptors,mammalian target of rapamycin(mTOR),programmed cell death receptor-1(PD-1),cyclin-dependent kinases(CDKs) and so on, whose levels are closely related to the prognosis of tumors. It has been found that the drugs targeting the above molecules can significantly improve the survival rate of cancer patients, and have the advantages of high selectivity, low toxicity and high therapeutic index. Targeted drugs, as new ones in the field of cancer, have achieved good efficacy in most tumor treatments. Oral cancer is an aggressive malignant tumour that is prone to relapse and metastasis. More than 90% of them are squamous cell carcinoma, and the 5-year survival rate remains at about 50%-60%.The proposing of targeted therapy opens up a new way for the treatment of oral cancer and brings dawn to patients with advanced diseases. Currently,a variety of targeted therapeutic drugs are being tested in various clinical trials in patients with oral squamous cell carcinoma(OSCC)·In this paper, we discuss the research progress of targeted therapeutic drugs in the treatment of OSCC in recent years.
Insights
Targeted therapy shows promise for oral cancer, particularly oral squamous cell carcinoma (OSCC). Drugs targeting over-expressed molecules like EGFR and VEGF offer new treatment avenues with improved survival rates.
Area of Science:
- Oncology
- Molecular Biology
- Biomedicine
Background:
- Malignant tumors exhibit over-expression of key molecules (e.g., EGFR, VEGF, mTOR, PD-1, CDKs) linked to prognosis.
- Targeted drugs offer high selectivity, low toxicity, and improved survival rates in cancer treatment.
- Oral cancer, predominantly OSCC, has a high recurrence rate and a 5-year survival rate of 50-60%.
Purpose of the Study:
- To review recent advancements in targeted therapy for oral squamous cell carcinoma (OSCC).
- To highlight the potential of targeted drugs in improving outcomes for advanced oral cancer patients.
Main Methods:
- Review of current research on targeted therapeutic drugs for OSCC.
- Analysis of clinical trials involving targeted therapies in OSCC patients.
Main Results:
- Targeted therapies are emerging as a promising treatment strategy for OSCC.
- Ongoing clinical trials are evaluating a variety of targeted drugs for OSCC treatment.
Conclusions:
- Targeted therapy represents a significant advancement in oral cancer treatment.
- This approach offers new hope for patients with advanced or recurrent OSCC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistant Cancers
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:34Inhibition of Cdk Activity